Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Studie van REGN5668 toegediend in combinatie met cemiplimab of REGN4018 bij volwassen vrouwen met recidiverende eierstokkanker

20 september 2026 bijgewerkt door: Regeneron Pharmaceuticals

Fase 1/2 studie van REGN5668 (MUC16xCD28, een costimulatoire bispecifieke) toegediend in combinatie met cemiplimab of REGN4018 (MUC16xCD3)

This study is researching an investigational drug called REGN5668 :

  • alone or,
  • combined with cemiplimab (also known as REGN2810) or,
  • combined with both cemiplimab and fianlimab (also known as REGN3767), or
  • combined with ubamatamab (also known as REGN4018), with or without sarilumab.

The main purposes of this study are to:

  • Learn about the safety and profile of any side effects from the study drugs and to determine the highest, safe dose that can be given to participants with ovarian cancer or cancer of the uterus
  • Look for signs that the study drugs can treat ovarian cancer or cancer of the uterus

This study has 2 parts. The purpose of Part 1 (Escalation) is to find the highest, safe dose of the study drug(s). The purpose of Part 2 (Expansion) is to use the doses chosen in Part 1. Participants with cancer of the uterus will only participate in Part 2.

The study is looking at several other research questions, including:

  • Side effects that may be experienced by participants taking REGN5668 alone and/or in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab
  • How REGN5668 works in the body either alone and/or in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab
  • How much of the study drugs (REGN5668, cemiplimab, fianlimab, ubamatamab) are in the blood
  • To see if REGN5668 in combination with cemiplimab, cemiplimab and fianlimab, or ubamatamab works to treat cancer

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Geschat)

612

Fase

  • Fase 2
  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • Vlaams-Brabant
      • Leuven, Vlaams-Brabant, België, 3000
        • Werving
        • Universitair Ziekenhuis Leuven
      • São Paulo, Brazilië, 01509-010
        • Werving
        • AC Camargo Cancer Center, Fundacao Antonio Prudente
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brazilië, 90619-900
        • Werving
        • Centro de Pesquisa em Oncologia PUCRS
    • São Paulo
      • Barretos, São Paulo, Brazilië, 14784-400
        • Werving
        • Fundacao Pio XII - Hospital de Cancer de Barretos
      • Sorocaba, São Paulo, Brazilië, 18065-100
        • Werving
        • Unimed Sorocaba
      • Villejuif, Frankrijk, 94805
        • Werving
        • Institut Gustave Roussy
    • Auvergne-Rhône
      • Pierre-Bénite, Auvergne-Rhône, Frankrijk, 69310
        • Werving
        • Hopital Lyon Sud
    • Bourgogne-Franche-Comté
      • Dijon, Bourgogne-Franche-Comté, Frankrijk, 21000
        • Werving
        • Centre Georges Francois Leclerc
    • New Aquitaine
      • Bordeaux, New Aquitaine, Frankrijk, 33076
        • Werving
        • Institut Bergonie
    • Normandy
      • Caen, Normandy, Frankrijk, 14076
        • Werving
        • Centre Francois Baclesse (CFB)
      • Girona, Spanje, 17007
        • Werving
        • Institut Catala dOncologia Girona
      • Madrid, Spanje, 28040
        • Werving
        • Hospital Universitario Fundacion Jimenez
      • Madrid, Spanje, 28040
        • Werving
        • Ciudad Universitaria
      • Madrid, Spanje, 28041
        • Werving
        • Hospital Universitario 12 de Octubre Universidad Complutense de Madrid UCM
    • A Coruna
      • Santiago de Compostela, A Coruna, Spanje, 15706
        • Werving
        • Hospital Clinico Universitario Santiago de Compostela
    • California
      • Duarte, California, Verenigde Staten, 91010
        • Werving
        • City of Hope Comprehensive Cancer Center
      • Irvine, California, Verenigde Staten, 92618
        • Werving
        • The City of Hope Orange County Lennar Foundation Cancer Center
      • Orange, California, Verenigde Staten, 92868
        • Werving
        • Chao Family Comprehensive Cancer Center
    • Florida
      • Tampa, Florida, Verenigde Staten, 33612
        • Voltooid
        • H. Lee Moffitt Cancer Center
    • Illinois
      • Chicago, Illinois, Verenigde Staten, 60611
        • Werving
        • Robert H. Lurie Comprehensive Cancer Center of Northwestern University
      • Chicago, Illinois, Verenigde Staten, 60637
        • Werving
        • University of Chicago Medical Center
    • Massachusetts
      • Boston, Massachusetts, Verenigde Staten, 02114
        • Werving
        • Massachusetts General Hospital
      • Boston, Massachusetts, Verenigde Staten, 02215
        • Werving
        • Dana Farber Cancer Institute Brookline Avenue
    • Michigan
      • Detroit, Michigan, Verenigde Staten, 48201
        • Werving
        • Karmanos Cancer Institute
    • New York
      • New York, New York, Verenigde Staten, 10065
        • Werving
        • Memorial Sloan Kettering Cancer Center
    • Ohio
      • Columbus, Ohio, Verenigde Staten, 43210
        • Werving
        • The Ohio State University Wexner Medical Center
    • Pennsylvania
      • Philadelphia, Pennsylvania, Verenigde Staten, 19104
        • Werving
        • Perelman School of Medicine at the University of Pennsylvania
    • Washington
      • Seattle, Washington, Verenigde Staten, 98109
        • Werving
        • Seattle Cancer Care Alliance at South Lake Union - G3630

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Vrouw

Beschrijving

Key Inclusion Criteria:

  1. Ovarian Cancer Cohorts Only: Has histologically or cytologically confirmed diagnosis of advanced epithelial ovarian cancer (except carcinosarcoma), primary peritoneal, or fallopian tube cancer that has received at least 1 line of platinum-based systemic therapy as defined in the protocol
  2. Expansion cohorts only: Has at least 1 lesion that is measurable by RECIST 1.1 as described in the protocol.
  3. Has a serum CA-125 level ≥2x ULN (in screening, not applicable to endometrial cohorts)
  4. Has adequate organ and bone marrow function as defined in the protocol
  5. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  6. Has a life expectancy of at least 3 months
  7. Endometrial Cancer Cohorts Only: histologically confirmed endometrial cancer that has progressed or recurrent after prior anti-PD-1 therapy and platinum-based chemotherapy as described in the protocol

Key Exclusion Criteria:

  1. Current or recent (as defined in the protocol) treatment with an investigational agent, systemic biologic therapy, or anti-cancer immunotherapy
  2. Has had another malignancy within the last 5 years that is progressing, requires active treatment, or has a high likelihood of recurrence as defined in the protocol
  3. Prior treatment with a Mucin 16 (MUC16)-targeted therapy
  4. Ovarian Expansion cohorts only: More than 5 prior lines of systemic therapy
  5. Has any condition that requires ongoing/continuous corticosteroid therapy as defined in the protocol within 1 week prior to the first dose of study drug
  6. Has ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments as defined in the protocol
  7. Has untreated or active primary brain tumor, CNS metastases, leptomeningeal disease, or spinal cord compression as defined in the protocol
  8. Has history of clinically significant cardiovascular disease as defined in the protocol
  9. Has known allergy or hypersensitivity to cemiplimab and/or components of study drug(s).

Note: Other protocol-defined Inclusion/Exclusion criteria apply

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Niet-gerandomiseerd
  • Interventioneel model: Sequentiële toewijzing
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Module 1

REGN5668 in combination with cemiplimab, or cemiplimab + fianlimab

Administer per the protocol

Andere namen:
  • ubletamig

Administer per the protocol

Andere namen:
  • REGN2810
  • Libtayo®

Administer per the protocol

Experimenteel: Module 2

REGN5668 and ubamatamab

Administer per the protocol

Andere namen:
  • ubletamig

Administer per the protocol

Andere namen:
  • REGN4018

Administer per the protocol

Andere namen:
  • Kevzara®

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Incidence of Dose Limiting Toxicities (DLT)
Tijdsspanne: 42 days

Dose escalation phase, Module 1

42 days
Incidence of DLTs
Tijdsspanne: 21 days post combination administration

Dose escalation phase, Module 2

21 days post combination administration
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Tijdsspanne: Through study completion, up to 5 years

Primary: Dose escalation phase Secondary: Dose expansion phase

Through study completion, up to 5 years
Incidence of Serious Adverse Events (SAEs)
Tijdsspanne: Through study completion, up to 5 years

Primary: Dose escalation phase Secondary: Dose expansion phase

Through study completion, up to 5 years
Incidence of deaths
Tijdsspanne: Through study completion, up to 5 years

Primary: Dose escalation phase Secondary: Dose expansion phase

Through study completion, up to 5 years
Incidence of laboratory abnormalities (Grade 3 or higher per National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE] version 5.0 [v5.0])
Tijdsspanne: Through study completion, up to 5 years

Primary: Dose escalation phase Secondary: Dose expansion phase

Through study completion, up to 5 years
Concentrations of REGN5668 in serum when dosed alone and in combination with cemiplimab or ubamatamab
Tijdsspanne: Through study completion, up to 5 years

Primary: Dose escalation phase

Through study completion, up to 5 years
Objective Response Rate (ORR) defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (Eisenhauer, 2009) of REGN5668 in combination with cemiplimab, cemiplimab + fianlimab, or ubamatamab (separately by cohort and combination)
Tijdsspanne: Through study completion, up to 5 years

Primary: Dose expansion phase

Through study completion, up to 5 years

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
ORR based on RECIST 1.1
Tijdsspanne: Through study completion, up to 5 years

Dose escalation phase

Through study completion, up to 5 years
Best Overall Response (BOR) based on RECIST 1.1
Tijdsspanne: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Duration Of Response (DOR) based on RECIST 1.1
Tijdsspanne: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Disease Control Rate (DCR) based on RECIST 1.1
Tijdsspanne: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Progression-Free Survival (PFS) based on RECIST 1.1
Tijdsspanne: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Cancer Antigen 125 (CA-125) change from baseline after treatment with REGN5668 in combinations with cemiplimab, cemiplimab + fianlimab, or ubamatamab (separately by cohort and combination)
Tijdsspanne: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Concentration of REGN5668 in serum over time when dosed alone and in combination with cemiplimab, cemiplimab + fianlimab, or ubamatamab
Tijdsspanne: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Presence or absence of anti-drug antibodies against REGN5668
Tijdsspanne: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Presence or absence of anti-drug antibodies against ubamatamab
Tijdsspanne: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Presence or absence of anti-drug antibodies against cemiplimab
Tijdsspanne: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years
Presence or absence of anti-drug antibodies against fianlimab
Tijdsspanne: Through study completion, up to 5 years

Dose escalation and expansion phases

Through study completion, up to 5 years

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Studie directeur: Clinical Trial Management, Regeneron Pharmaceuticals

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

8 december 2020

Primaire voltooiing (Geschat)

8 november 2028

Studie voltooiing (Geschat)

8 november 2028

Studieregistratiedata

Eerst ingediend

9 oktober 2020

Eerst ingediend dat voldeed aan de QC-criteria

9 oktober 2020

Eerst geplaatst (Werkelijk)

19 oktober 2020

Updates van studierecords

Laatste update geplaatst (Werkelijk)

24 september 2026

Laatste update ingediend die voldeed aan QC-criteria

20 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

IPD-tijdsbestek voor delen

When Regeneron has:

  • received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
  • made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
  • the legal authority to share the data, and
  • ensured the ability to protect participant privacy

IPD-toegangscriteria voor delen

Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

IPD delen Ondersteunend informatietype

  • LEERPROTOCOOL
  • SAP
  • ICF
  • ANALYTIC_CODE
  • MVO

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren